title: Relation of the -514C/T polymorphism in the hepatic lipase gene to serum HDL and LDL cholesterol levels in postmenopausal women under hormone replacement therapy.
abstract: Hepatic lipase (HL) is a lipolytic enzyme that catalyzes hydrolysis of triglycerides and phospholipids in all major classes of lipoproteins. Recently, a -514C/T polymorphism in the promoter region of the HL gene was found to be associated with variations in hepatic lipase activity and serum high density lipoprotein cholesterol (HDL-C) levels. Postmenopausal hormone replacement therapy (HRT) has known favorable effects on serum lipid and lipoprotein levels. In this study, we examined the relation between the -514C/T polymorphism and serum lipid and lipoprotein levels in postmenopausal women prior to and after 3 months of HRT. Significant associations between the -514 C/T polymorphism and HDL-C, low density lipoprotein cholesterol (LDL-C) and apolipoprotein A-I (apo A-I) levels were observed before and/or after 3 months of HRT. With HRT, serum total cholesterol (TC), LDL-C and apolipoprotein B (apo B) levels were reduced significantly (P=0.0001), and HDL-C and apo A-I levels were increased significantly (P=0.0001). However, the degrees of change in lipid and lipoprotein levels due to HRT did not differ significantly between the HL genotypes.
authors.affiliation: Department of Medical Genetics, Institute of Basic Medical Sciences, University of Tsukuba, Tsukuba 305-8575, Japan. kkimiko@md.tsukuba.ac.jp
authors.forename: Kimiko
authors.initials: K
authors.lastname: Yamakawa-Kobayashi
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Somekawa
authors.forename: Mitsuko
authors.initials: M
authors.lastname: Fujimura
authors.forename: Shigeo
authors.initials: S
authors.lastname: Tomura
authors.forename: Tadao
authors.initials: T
authors.lastname: Arinami
authors.forename: Hideo
authors.initials: H
authors.lastname: Hamaguchi
mesh_terms: D000328:Adult; D000368:Aged; D000483:Alleles; D016632:Apolipoprotein A-I / Q000097:blood / Q000187:drug effects; D001055:Apolipoproteins B / Q000097:blood / Q000187:drug effects; D008076:Cholesterol, HDL / Q000097:blood* / Q000187:drug effects*; D008078:Cholesterol, LDL / Q000097:blood* / Q000187:drug effects*; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D005260:Female; D005838:Genotype; D006801:Humans; D007564:Japan; D008049:Lipase / Q000235:genetics*; D008099:Liver / Q000098:blood supply* / Q000201:enzymology*; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D008875:Middle Aged; D011110:Polymorphism, Genetic / Q000187:drug effects / Q000235:genetics; D017698:Postmenopause / Q000097:blood* / Q000235:genetics*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D016387:Women's Health
chemical_list: D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004966:Estrogens, Conjugated (USP); D014280:Triglycerides; D017258:Medroxyprogesterone Acetate; D008049:Lipase